Viking Therapeutics' dual GLP-1/GIP receptor agonist VK2735 showed promising weight reduction in the phase 2 VENTURE trial, with the 15 mg dose contributing to a 14% reduction in body weight from baseline to week 13.
An overview of the journey and significant events of 2023 that have catapulted semaglutide from a type 2 diabetes agent to the topic of discussions among circles across healthcare and beyond.